Chest · 2025
Impact of Noninvasive Ventilation Before and After Cardiac Surgery for Preventing Cardiac and Pulmonary Complications: A Clinical Randomized Trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Goret Marion, Pluchon Kevin, Le Mao Raphaël, Badra Ali, Oilleau Jean-Ferréol, Morvan Yohann, Beaumont Marc, Desanglois Gwenaëlle, Guegan Marie, Barnier Aude, Gut-Gobert Christophe, Tromeur Cécile, Leroyer Christophe, Choplain Jean-Noël, Khalifa Ahmed, Bezon Eric, Couturaud Francis
Аннотация
BACKGROUND: The immediate postoperative period after heart surgery poses a substantial risk of life-threatening complications, notably acute pulmonary and cardiac failure. Use of noninvasive ventilation (NIV) may reduce the incidence of pulmonary or heart failure, or both.
RESEARCH QUESTION: Is the use of NIV before and after cardiac surgery associated with a lower rate of acute pulmonary and heart failure in patients at risk of postoperative complications?
STUDY DESIGN AND METHODS: We designed a prospective, randomized, monocentric trial comparing preoperative and postoperative NIV in cardiac surgery with standard care. Adult patients classified as being at risk of postoperative cardiac or pulmonary failure were allocated to receive NIV for 5 days before and 5 days after surgery in addition to usual care vs usual care alone. The primary outcome was the composite of predefined and adjudicated cardiorespiratory failure at 1 month after cardiac surgery.
RESULTS: Two hundred sixteen patients were included. During the 1-month follow-up period after surgery, the composite outcome occurred in 59 of 107 patients (55.1%) in the NIV group and in 87 of 109 patients (79.8%) in the no NIV group (relative risk, 0.69; 95% CI, 0.57-0.84; P < .001). The benefit persisted at 3 months. No difference between the 2 groups was found in terms of intubation need and length of hospital stay in cardiac and pulmonary surgery ICUs and in cardiac and pulmonary surgery units.
INTERPRETATION: Our results indicate that the use of NIV before and after cardiac surgery reduces the rate of cardiopulmonary failure after high-risk cardiac surgery.
CLINICAL TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02302300; URL: www.
CLINICALTRIALS: gov.
RESEARCH QUESTION: Is the use of NIV before and after cardiac surgery associated with a lower rate of acute pulmonary and heart failure in patients at risk of postoperative complications?
STUDY DESIGN AND METHODS: We designed a prospective, randomized, monocentric trial comparing preoperative and postoperative NIV in cardiac surgery with standard care. Adult patients classified as being at risk of postoperative cardiac or pulmonary failure were allocated to receive NIV for 5 days before and 5 days after surgery in addition to usual care vs usual care alone. The primary outcome was the composite of predefined and adjudicated cardiorespiratory failure at 1 month after cardiac surgery.
RESULTS: Two hundred sixteen patients were included. During the 1-month follow-up period after surgery, the composite outcome occurred in 59 of 107 patients (55.1%) in the NIV group and in 87 of 109 patients (79.8%) in the no NIV group (relative risk, 0.69; 95% CI, 0.57-0.84; P < .001). The benefit persisted at 3 months. No difference between the 2 groups was found in terms of intubation need and length of hospital stay in cardiac and pulmonary surgery ICUs and in cardiac and pulmonary surgery units.
INTERPRETATION: Our results indicate that the use of NIV before and after cardiac surgery reduces the rate of cardiopulmonary failure after high-risk cardiac surgery.
CLINICAL TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02302300; URL: www.
CLINICALTRIALS: gov.